Article Text
Editorial
Polypill strategy at the heart of cardiovascular secondary prevention
Statistics from Altmetric.com
Footnotes
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests BI and VF have no personal conflicts of interest to declare. JMC has received speaker fees and travel support from Ferrer. The CNIC is a non-profit public institution that receives royalties for the sales of a polypill (Trinomia) composed of aspirin, ramipril and atorvastatin, but no CNIC researcher has direct interests or receives any personal benefits.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Cardiac risk factors and prevention